RemeGen Co., Ltd.
9995.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.69B
Close$
Share Statistics
| Market cap | $59.69 Billion |
|---|---|
| Enterprise Value | $58.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.29 |
| Beta | 0.46 |
| Outstanding Shares | 560,164,434 |
Return
| Return on Equity | 69.54% |
|---|---|
| Return on Assets | 58.71% |
| Return on Invested Capital | 57.23% |
Valuation & Multiples
| P/E Ratio | 10.38 |
|---|---|
| PEG | -0.45 |
| Price to Sales | 4.76 |
| Price to Book Ratio | 4.76 |
| Enterprise Value to Revenue | 7.38 |
| Enterprise Value to EBIT | 12.09 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$3.10 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$6.53 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About RemeGen Co. Ltd. Class A
3,048 employees
CEO: Jian Min Fang RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company of...